Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Lumentum (LITE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Lumentum — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.64 (market cap $12.58B), while Lumentum trades at $1,128.2 (market cap $94.99B). The key difference: Lumentum is far larger — about 7.6× Halozyme Therapeutics Inc. Common Stock's market cap, and Lumentum is more actively traded (4,855,776 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Lumentum for 4 Days on average.
| HALO | LITE | |
|---|---|---|
Market Cap | $12.58B | $94.99B |
Volume | 2,179,278 | 4,855,776 |
Sector | Health | Technology |
52-Week High | $115.22 | $1.13K |
52-Week Low | $61.63 | $149.61 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $14.49B | $93.92B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Lumentum
Lumentum develops photonic products, including optical components, transceivers, and lasers. Its technologies support data centers, communications networks, industrial manufacturing, and sensing applications.
Read more on LITE →
